Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11255-024-04185-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Newer Insulin Preparations and Insulin Analogs.
Cureus
November 2024
Department of Pharmacology, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, IND.
Diabetes mellitus represents a significant and growing global health challenge, with its prevalence steadily increasing. Insulin therapy remains a cornerstone of diabetes management. Since its discovery in 1921, insulin has undergone substantial advancements, evolving from crude animal extracts to highly refined recombinant formulations and biosimilars.
View Article and Find Full Text PDFBeyond fat: Does semaglutide affect lean mass?
Clin Nutr
January 2025
Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:
Article Synopsis
- The paper discusses the effects of semaglutide, a GLP-1 receptor agonist, particularly focusing on its influence on lean mass in addition to its weight loss benefits.
- While some studies show that semaglutide leads to a reduction in both lean and fat mass, others indicate an increase in lean mass relative to total body mass.
- The mixed results highlight the need for further research, especially given the increasing use of semaglutide in treatments.
Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database.
Endocrine
November 2024
Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
Article Synopsis
- The study aimed to explore the link between GLP-1 receptor agonists (GLP-1 RAs) and eye-related adverse drug reactions (OADRs), utilizing data from the FDA's reporting system from 2018 to 2023.
- It found 5003 reported OADRs related to GLP-1 RAs, with significant findings for drugs like semaglutide and liraglutide, suggesting a need for careful monitoring and early intervention.
- The conclusion highlights the crucial need for eye health monitoring in patients on GLP-1 RAs and suggests that regulatory agencies should update drug labels to reflect these potential risks.
Emerging Therapies for Non-Alcoholic Steatohepatitis (NASH): A Comprehensive Review of Pharmacological and Non-Pharmacological Approaches.
Cureus
September 2024
Medicine and Surgery, King Edward Medical University, Lahore, PAK.
Non-alcoholic steatohepatitis (NASH) has emerged as a significant global health concern, closely linked to the obesity epidemic and metabolic syndrome. This review explores emerging therapies for NASH that go beyond traditional lifestyle modifications. The complex pathophysiology of NASH, involving insulin resistance, lipotoxicity, oxidative stress, and chronic inflammation, offers multiple targets for therapeutic intervention.
View Article and Find Full Text PDFComparative Efficacy and Safety of Weekly GLP-1/GIP Agonists vs. Weekly Insulin in Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.
Biomedicines
August 2024
Department of Medicine, Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Background: Diabetes mellitus (DM) significantly impacts global health due to its complications and the economic burden it places on healthcare systems. The rise of novel once-weekly diabetes medications with different mechanisms of action necessitates an evaluation of their relative efficacy and safety.
Objectives: This study compares the efficacy and tolerability of once-weekly insulin analogs (icodec and BIF) with once-weekly GLP-1/GIP agonists (semaglutide, exenatide, tirzepatide, dulaglutide) in managing type 2 diabetes mellitus (T2DM).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!